公开(公告)号：US20240270825A1

公开(公告)日：2024-08-15

申请号：US18237817

申请日：2023-08-24

Applicant: Centivax, Inc.

Inventor： Jacob Glanville ,  Shahrad Daraeikia ,  I-Chieh Wang ,  Sindy Andrea Liao Chan ,  Jean-Philippe Bürckert ,  Sawsan Youssef

IPC: C07K16/10 ,  A61P31/14 ,  G01N33/569

CPC classification number: C07K16/1003 ,  A61P31/14 ,  G01N33/56983 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92 ,  G01N2333/165 ,  G01N2469/10

Abstract: This disclosure provides antibodies and that can be administered to an individual that is infected with a virus. Antibodies herein can be capable of treating or curing the virus, and which may provide protection against the virus for up to several weeks. Antibodies herein can be used to diagnose a SARS-CoV-2 infection.

公开(公告)号：US12043647B2

公开(公告)日：2024-07-23

申请号：US18067525

申请日：2022-12-16

Applicant: Centivax, Inc.

Inventor： Jacob E. Glanville

IPC: A61K39/155 ,  A61K35/76 ,  A61K38/46 ,  A61K39/00 ,  A61K39/12 ,  A61K39/21 ,  A61K39/245 ,  C07K14/005 ,  C12N7/00 ,  G16B20/30 ,  G16B30/00 ,  G16B30/10 ,  G16B35/00 ,  G16B35/10 ,  G16C20/60 ,  G16B20/00

CPC classification number: C07K14/005 ,  A61K38/46 ,  A61K39/0011 ,  A61K39/12 ,  A61K39/21 ,  C12N7/00 ,  G16B20/30 ,  G16B30/00 ,  G16B30/10 ,  G16B35/00 ,  G16B35/10 ,  G16C20/60 ,  A61K2039/515 ,  A61K2039/5154 ,  A61K2039/53 ,  A61K2039/575 ,  A61K2039/70 ,  C12N2740/16034 ,  C12N2740/16071 ,  C12N2740/16122 ,  C12N2740/16134 ,  C12N2760/16122 ,  C12N2760/16134 ,  C12Y306/05002 ,  G16B20/00

Abstract: The present disclosure provides compositions and methods for the generation of an antibody or immunogenic composition, such as a vaccine, through epitope focusing by variable effective antigen surface concentration. Generally, the composition and methods of the disclosure comprise three steps: a “design process” comprising one or more in silico bioinformatics steps to select and generate a library of potential antigens for use in the immunogenic composition; a “formulation process”, comprising in vitro testing of potential antigens, using various biochemical assays, and further combining two or more antigens to generate one or more immunogenic compositions; and an “administering” step, whereby the immunogenic composition is administered to a host animal, immune cell, subject or patient. Further steps may also be included, such as the isolation and production of antibodies raised by host immune response to the immunogenic composition.

公开(公告)号：US20240294618A1

公开(公告)日：2024-09-05

申请号：US18481129

申请日：2023-10-04

Applicant: Centivax, Inc.

Inventor： Jacob E. Glanville ,  Timothy Paul Friede ,  David Tsao ,  Sindy Andrea Liao Chan ,  I-Chieh Wang

IPC: C07K16/18 ,  A61K31/404 ,  A61K39/00 ,  A61P39/02 ,  G01N33/68

CPC classification number: C07K16/18 ,  A61K31/404 ,  A61P39/02 ,  G01N33/6857 ,  A61K2039/505 ,  C07K2317/565 ,  C07K2317/76 ,  G01N2333/4616 ,  G01N2333/4646

Abstract: This disclosure provides antibodies and antigen-binding fragments that can be administered to a subject that has been bitten by a venomous snake. Antibodies and antigen-binding fragments herein can be capable of treating or curing the subject and may provide protection against snake venom for up to several weeks. A combination or population of antibodies and antigen-binding fragments can be administered to the subject where the type of snake is not known or where a subject has been bitten by more than one species of snake. This disclosure further provides methods for identification of such broadly-neutralizing antibodies.

公开(公告)号：US11028150B1

公开(公告)日：2021-06-08

申请号：US15931642

申请日：2020-05-14

Applicant: Centivax, Inc.

Inventor： Jacob Glanville ,  Shahrad Daraeikia ,  I-Chieh Wang ,  Sindy Andrea Liao Chan ,  Jean-Philippe Bürckert ,  Sawsan Youssef

IPC: C07K16/10 ,  A61K39/42 ,  G01N33/569 ,  A61P31/14 ,  A61K39/00

Abstract: This disclosure provides antibodies and antigen-binding fragments that are derived from 2dd8 and that can be administered to an individual that is infected or suspected of being infected with a virus. Antibodies and antigen-binding fragments herein can be capable of treating or curing the virus, and which may provide protection against the virus for up to several weeks. Antibodies and antigen-binding fragments herein can be used to diagnose a SARS CoV-2 infection.

公开(公告)号：US20230272051A1

公开(公告)日：2023-08-31

申请号：US17934785

申请日：2022-09-23

Applicant: Centivax, Inc.

Inventor： Jacob Glanville ,  Shahrad Daraeikia ,  I-Chieh Wang ,  Sindy Andrea Liao Chan ,  Jean-Philippe Bürckert ,  Sawsan Youssef

IPC: C07K16/10

CPC classification number: C07K16/1018 ,  C07K2317/565

Abstract: This disclosure provides antibodies and antigen-binding fragments that can be administered to an individual that is infected or suspected of being infected with a virus. Antibodies and antigen-binding fragments herein can be capable of treating or curing the virus, and which may provide protection against the virus for up to several weeks. Antibodies and antigen-binding fragments herein can be used to diagnose a SARS-CoV-2 infection.

公开(公告)号：US11560409B2

公开(公告)日：2023-01-24

申请号：US17070334

申请日：2020-10-14

Applicant: Centivax, Inc.

Inventor： Jacob E. Glanville

IPC: A61K39/12 ,  A61K39/00 ,  C07K14/005 ,  A61K39/21 ,  C12N7/00 ,  G16B30/00 ,  G16B35/00 ,  G16C20/60 ,  G16B35/10 ,  G16B20/30 ,  G16B30/10 ,  A61K38/46 ,  G16B20/00

Abstract: The present disclosure provides compositions and methods for the generation of an antibody or immunogenic composition, such as a vaccine, through epitope focusing by variable effective antigen surface concentration. Generally, the composition and methods of the disclosure comprise three steps: a “design process” comprising one or more in silico bioinformatics steps to select and generate a library of potential antigens for use in the immunogenic composition; a “formulation process”, comprising in vitro testing of potential antigens, using various biochemical assays, and further combining two or more antigens to generate one or more immunogenic compositions; and an “administering” step, whereby the immunogenic composition is administered to a host animal, immune cell, subject or patient. Further steps may also be included, such as the isolation and production of antibodies raised by host immune response to the immunogenic composition.

公开(公告)号：US11053304B1

公开(公告)日：2021-07-06

申请号：US15931648

申请日：2020-05-14

Applicant: Centivax, Inc.

Inventor： Jacob Glanville ,  Shahrad Daraeikia ,  I-Chieh Wang ,  Sindy Andrea Liao-Chan ,  Jean-Philippe Bürckert ,  Sawsan Youssef

IPC: C07K16/10 ,  A61K39/42 ,  G01N33/569 ,  A61P31/14 ,  A61K39/00

Abstract: This disclosure provides antibodies and antigen-binding fragments that are derived from 6nb6 and that can be administered to an individual that is infected or suspected of being infected with a virus. Antibodies and antigen-binding fragments herein can be capable of treating or curing the virus, and which may provide protection against the virus for up to several weeks. Antibodies and antigen-binding fragments herein can be used to diagnose a SARS CoV 2 infection.

公开(公告)号：US11034762B1

公开(公告)日：2021-06-15

申请号：US15931649

申请日：2020-05-14

Applicant: Centivax, Inc.

Inventor： Jacob Glanville ,  Shahrad Daraeikia ,  I-Chieh Wang ,  Sindy Andrea Liao Chan ,  Jean-Philippe Bürckert ,  Sawsan Youssef

IPC: A61K39/42 ,  C07K16/28 ,  G01N33/569 ,  C07K16/10 ,  A61K39/00

Abstract: This disclosure provides antibodies that are derived from CFR3022 and that can be administered to an individual that is infected with a virus. Antibodies herein can be capable of treating or curing the virus, and which may provide protection against the virus for up to several weeks. Antibodies herein can be used to diagnose a SARS CoV 2 infection.

公开(公告)号：US20230312658A1

公开(公告)日：2023-10-05

申请号：US18067525

申请日：2022-12-16

Applicant: Centivax, Inc.

Inventor： Jacob E. Glanville

IPC: C07K14/005 ,  A61K39/12 ,  A61K39/21 ,  A61K38/46 ,  G16B30/10 ,  A61K39/00 ,  G16C20/60 ,  C12N7/00 ,  G16B35/00 ,  G16B20/30 ,  G16B30/00 ,  G16B35/10 ,  G16B20/00

CPC classification number: C07K14/005 ,  A61K38/46 ,  A61K39/0011 ,  A61K39/12 ,  A61K39/21 ,  C12N7/00 ,  G16B20/30 ,  G16B30/00 ,  G16B30/10 ,  G16B35/00 ,  G16B35/10 ,  G16C20/60 ,  A61K2039/515 ,  A61K2039/5154 ,  A61K2039/53 ,  A61K2039/575 ,  A61K2039/70 ,  C12N2740/16034 ,  C12N2740/16071 ,  C12N2740/16122 ,  C12N2740/16134 ,  C12N2760/16122 ,  C12N2760/16134 ,  C12Y306/05002 ,  G16B20/00

Abstract: The present disclosure provides compositions and methods for the generation of an antibody or immunogenic composition, such as a vaccine, through epitope focusing by variable effective antigen surface concentration. Generally, the composition and methods of the disclosure comprise three steps: a “design process” comprising one or more in silico bioinformatics steps to select and generate a library of potential antigens for use in the immunogenic composition; a “formulation process”, comprising in vitro testing of potential antigens, using various biochemical assays, and further combining two or more antigens to generate one or more immunogenic compositions; and an “administering” step, whereby the immunogenic composition is administered to a host animal, immune cell, subject or patient. Further steps may also be included, such as the isolation and production of antibodies raised by host immune response to the immunogenic composition.

公开(公告)号：US20220088175A1

公开(公告)日：2022-03-24

申请号：US17399041

申请日：2021-08-10

Applicant: Centivax, Inc.

Inventor： Jacob GLANVILLE ,  Sarah IVES ,  Michal IZHAKY ,  Sawsan YOUSSEF ,  Jean-Philippe BÜRCKERT

IPC: A61K39/145 ,  C12N7/00

Abstract: Described herein are compositions of and methods of making vaccines which can provide broad serological reactivity an inverse dose response, and a swarm effect.